NCT05094011View on ClinicalTrials.gov

Evaluating Safety, Tolerability, and Efficacy of Autologous MitoCell Transplantation in Subjects With Idiopathic Parkinson's Disease

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

March 1, 2026

Primary Completion Date

September 30, 2027

Study Completion Date

July 31, 2028

Conditions
Idiopathic Parkinson's Disease
Interventions
BIOLOGICAL

Aadipose-Derived Mesenchymal Stem Cells

Stereotactic intrastriatal implantation of 3×10\^7 per hemisphere (total 6×10\^7 cells) or 1×10\^8 per hemisphere (total 2×10\^8 cells) autologous TM01-treated adipose-derived mesenchymal stem cells (MitoCell).

All Listed Sponsors
lead

Taiwan Mitochondrion Applied Technology Co., Ltd.

INDUSTRY